A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

People who used lipophilic (fat-soluble) statins like atorvastatin and simvastatin had the greatest outcomes and ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

A new study has found that combining statins - the first-line treatment for high cholesterol - and ezetimibe, another drug ...

Jersey City-based Character Biosciences announced this week it completed a $93 million Series B financing round.

Researchers Find Cholesterol-Lowering Drugs Have No Effect on Kidney Function Jan. 27, 2025 — Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team has ...

Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important ...

As an adenosine triphosphate-citrate lyase (ACL) inhibitor, this medication works by blocking a protein in your liver from making LDL cholesterol. It’s the first drug in the ACL inhibitor class ...